Compounded tirzepatide, all-inclusive from $269/month.

Compounded tirzepatide at REMEVi is all-inclusive: $379/month month-to-month, $339/month on the 12-week plan, or $269/month on the 52-week plan (Best Value). Every plan covers the licensed clinical evaluation, the medication itself, syringes and supplies, monthly free shipping, and a bilingual care coordinator. No lab fees, no consultation fees, no surprise renewal charges. Direct-pay only — no insurance billing. HSA/FSA cards accepted.

Brand-name Zepbound® and Mounjaro® are FDA-approved finished products manufactured by Eli Lilly under New Drug Application approval, with the full cost of pharma R&D, marketing, and supply chain priced into the retail rate (roughly $1,000–$1,400/month without insurance). Compounded tirzepatide is a non-FDA-approved preparation made by state-licensed US compounding pharmacies under individual prescriptions from licensed providers. The regulatory path, supply chain, and pricing model are different. Compounded preparations are not generic versions of the branded products and have not been clinically studied as finished products.

Every REMEVi compounded tirzepatide plan includes: (1) the licensed clinical evaluation by a US board-certified provider; (2) the compounded medication itself, prepared by an FDA-registered 503A or 503B compounding pharmacy; (3) all injection supplies (vial, syringes, alcohol pads, sharps disposal guidance); (4) monthly discreet shipping to your door; (5) unlimited access to a bilingual care coordinator with a 2-hour response SLA; (6) provider check-ins during titration; (7) the patient portal for messaging and refills. No lab fees, no consultation fees, no shipping fees, no renewal-surprise charges.

No. REMEVi publishes a single all-inclusive monthly price. There is no lab fee, no consultation fee, no shipping fee, no annual fee, and no cancellation fee. You can cancel anytime through the patient portal in two clicks. If labs are clinically required (rare for weight management), they can be ordered through your provider but are not bundled — you would pay only what the lab company bills directly. There is no language surcharge — Spanish service costs the same as English service.

REMEVi is direct-pay and does not bill commercial or government insurance. We chose this model because most insurance plans either do not cover compounded GLP-1 medications at all or require costly prior authorizations that frequently get denied. HSA and FSA cards are accepted at checkout. Many patients find REMEVi pricing is competitive with or lower than their insurance co-pays for brand-name Zepbound or Mounjaro once the full cost of in-person visits, labs, and medication tiers are added up. Your care coordinator can provide an HSA-formatted receipt on request.

The longer commitment you choose, the lower the monthly price: $379 monthly → $339 on 12-week → $269 on 52-week (Best Value). The price is locked at signup — no surprise increases mid-plan. If you switch from monthly to a 52-week plan after starting, the per-month rate drops on the next billing cycle. If you cancel a long-commitment plan early, you simply stop being billed at the next cycle; there is no early-cancellation fee.